Drug Type Small molecule drug |
Synonyms ELE-PSILO, ELE-Psilo+, fast-releasing psilocybin oral formulation(Cybin) + [29] |
Action antagonists, agonists |
Mechanism 5-HT1A receptor antagonists(Serotonin 1a (5-HT1a) receptor antagonists), 5-HT2A receptor agonists(Serotonin 2a (5-HT2a) receptor agonists), 5-HT2C receptor agonists(Serotonin 2c (5-HT2c) receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Innovative Licensing and Access Pathway (United Kingdom) |
Molecular FormulaC12H17N2O4P |
InChIKeyQVDSEJDULKLHCG-UHFFFAOYSA-N |
CAS Registry520-52-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Psilocybin | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder, Major | Phase 3 | United States | 05 Mar 2024 | |
Depressive Disorder, Treatment-Resistant | Phase 3 | United States | 19 Jan 2023 | |
Stimulant abuse | Phase 2 | - | 01 Jan 2025 | |
Opioid abuse | Phase 2 | - | 01 Dec 2024 | |
Irritable Bowel Syndrome | Phase 2 | United States | 17 Jan 2024 | |
Borderline Personality Disorder | Phase 2 | United States | 01 Nov 2023 | |
Neoplasms | Phase 2 | United States | 23 Oct 2023 | |
Fibromyalgia | Phase 2 | United States | 27 Sep 2023 | |
Generalized anxiety disorder | Phase 2 | Canada | 24 Jan 2023 | |
Mild depression | Phase 2 | Canada | - | 01 Jan 2023 |
Phase 1/2 | 55 | Counseling+Psilocybin | ldujwrqypu = ogamrgboqa zwxqeuhsxz (qfkivsukkm, amarwamgin - zrfhzgusop) View more | - | 30 Apr 2025 | ||
Phase 2 | 17 | uiasbrhvcm(wkmwvrrheu) = xhfpfpbbql atkbdxnkky (htmpfmabgp, acoksnnnur - znwnwxckpo) View more | - | 16 Apr 2025 | |||
Phase 2 | 37 | Psilocybin (25 mg) | sflkishsvm(lssppcpphb) = bqaievwasy xnrcgmjnvf (udzquwskck, 14.31 - 19.29) View more | Negative | 01 Apr 2025 | ||
Placebo (mannitol) | sflkishsvm(lssppcpphb) = pddlsxtcvf xnrcgmjnvf (udzquwskck, 10.97 - 16.63) View more | ||||||
Phase 3 | 30 | (Psilocybin Arm) | tzjikahsne(qwtcunbyzk) = qxoazydaoe cipzlprcwk (bpxnijcbwj, 7.84) View more | - | 18 Mar 2025 | ||
Active placebo (Placebo) | tzjikahsne(qwtcunbyzk) = lsumebbglx cipzlprcwk (bpxnijcbwj, 7.32) View more | ||||||
Phase 2 | 10 | znsgwtflzw(hijrbbyrue) = ktvfqcqemx isypmoxtiq (cyatxawqhs, −61.1 - −13.9) View more | Positive | 17 Mar 2025 | |||
Phase 2 | 15 | gpbuuesssc(kwpqqpujpj) = ltowyefosz ywgfrvfdyh (bhqkmkklkk ) View more | Positive | 01 Jan 2025 | |||
Phase 2 | 59 | Psilocybin + Placebo (Psilocybin) | vkrytrihph(gszekhluxn) = dltvaslkpx vhfjiitypg (hxhcxrrhtl, 0.45) View more | - | 24 Oct 2024 | ||
(Escitalopram) | vkrytrihph(gszekhluxn) = heykzczamj vhfjiitypg (hxhcxrrhtl, 0.62) View more | ||||||
NCT03429075 (Literature) Manual | Phase 2 | 59 | Psilocybin combined with psychological support | sxkqscbzam(jvardrrwsp): Difference = 1.51 (95% CI, -1.35 to 4.38), P-Value = 0.311 View more | Positive | 21 Sep 2024 | |
Escitalopram combined with psychological support | |||||||
Phase 1 | 10 | jpiuitakak(ydcldeyaom) = Two participants developed asymptomatic hypoglycemia at post-treatment, which resolved within 24 h. No other clinically significant changes were observed in laboratory values. All AEs were mild and transient in nature. bwnhmoujxn (mhhocapckw ) | Positive | 01 Jul 2024 | |||
Phase 2 | 22 | COMP360 psilocybin | kkmhiclxuf(ftxbbqawrt) = There were no treatment-emergent serious adverse events. uaislvefkp (lptwyunugi ) Met View more | Positive | 08 May 2024 |